| Abstract: |
Despite recent advances in the conventional management of ovarian cancer, this disease remains the leading cause of death among the gynecologic malignancies, killing more American women each year than all other gynecologic cancers combined. As a tumor arising from a nonessential organ that remains primarily confined to the peritoneal cavity, ovarian cancer makes an attractive target for monoclonal antibodies (MoAb). Several MoAb have been developed that have actual or potential clinical use in the management of ovarian cancer. Serum assays using a MoAb against an ovarian cancer‐associated antigen (CA 125) are currently in routine clinical use for monitoring the course of disease in women with known ovarian cancer. Such assays may play a role in multi‐technique screening programs. Radiolabeled antibodies are under study for use in external imaging or intraoperative detection of ovarian cancer. Isotope‐labeled antibodies also are being evaluated in the treatment of ovarian cancer as are antibodies coupled to drugs or biologic toxins. Some antibodies may have direct antitumor effects through binding to biologically active receptors or through immune effector functions. The use of antibody fragments, chimeric antibodies, human antibodies, and genetically engineered antibodies is under active investigation. MoAb have important potential for improving the diagnosis, monitoring of response to therapy, and treatment of ovarian cancer. Copyright © 1993 American Cancer Society |
| Keywords: |
conference paper; ovarian neoplasms; ovary cancer; tumor markers, biological; antineoplastic activity; immunoreactivity; tumor marker; monoclonal antibodies; monoclonal antibody; antibodies, monoclonal; diagnostic value; ca 125 antigen; radioimmunotherapy; receptor binding; radioimmunoassay; radioimmunodetection; tumor markers; radioimmunoscintigraphy; human; female; priority journal; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; ovarian neoplasia
|
